AbbVie Pays $10.9 Billion Cash for Apogee Therapeutics at ~50% Premium

AbbVie (ABBV) announced June 22 that it has agreed to acquire clinical-stage biotech Apogee Therapeutics (APGE) for $135.11 per share in cash, implying a total equity value of approximately $10.9 billion.^[Bloomberg] Apogee shares leapt as much as 48% in premarket trading Monday, rapidly closing in on the offer price.^[CNBC]

Deal Terms and Premium

The transaction is structured as an all-cash deal with the following terms:

• Offer price: $135.11 per share in cash
• Total consideration: ~$10.9 billion in equity value
• Premium: ~49% above Apogee's prior-day closing price of $90.38
• Expected close: Q3 2026, subject to customary closing conditions including Apogee shareholder approval and regulatory clearance

Multiple outlets described the deal as a major commitment by AbbVie to bolster its immunology franchise.^{[U.S. News / Reuters]}

Apogee's Pipeline

Apogee Therapeutics is a clinical-stage biotech focused on immunology and inflammation (I&I). The deal centers on its pipeline:

• Zumilokibart (APG777): Apogee's lead program — a subcutaneous, half-life-extended anti-IL-13 monoclonal antibody targeting atopic dermatitis, asthma, and other IL-13-driven inflammatory diseases
• APG333 and APG273: two additional candidates targeting high-need inflammatory indications

In its Phase 2 APEX trial for moderate-to-severe atopic dermatitis, zumilokibart met both primary and secondary endpoints at Week 16, with significantly greater reductions in disease severity versus placebo.^[BioSpace] Apogee has indicated it plans to initiate a Phase 3 trial in moderate-to-severe atopic dermatitis in the second half of 2026, pending regulatory feedback.

Competitive Landscape

Atopic dermatitis is widely regarded as one of the largest and still-underpenetrated markets in I&I. According to BioPharma Dive, Apogee's antibody could require less frequent dosing than existing therapies — a potential differentiator versus Sanofi/Regeneron's Dupixent and Eli Lilly's (LLY) Ebglyss.^{[BioPharma Dive]}

For AbbVie, the deal is seen as a pipeline-building move as Humira's patent exclusivity has progressively eroded, leaving the company under longstanding pressure to identify its next growth drivers in immunology.^{[Pharmaceutical Executive]}

Broader M&A Context

June 22 also saw another sizable deal: CRH announced it would acquire Texas-based Arcosa (ACA) for approximately $8.5 billion, sending Arcosa shares up roughly 7%, according to CNBC.^[CNBC] The broader market pulled back that day, with the S&P 500 closing down ~0.37% at 7,472.79 and the Nasdaq Composite off ~1.32% at 26,166.60.

The transaction still requires a Apogee shareholder vote and regulatory clearance before it can close in Q3. The progression of zumilokibart's Phase 3 program will be the other key milestone to watch.

This content is for informational purposes only and does not constitute investment advice, trading advice, or any guarantee of returns.